Cardiff Oncology Inc (NASDAQ: CRDF) on Monday, plunged -6.82% from the previous trading day, before settling in for the closing price of $3.08. Within the past 52 weeks, CRDF’s price has moved between $1.90 and $4.99.
A company in the Healthcare sector has jumped its sales by 19.36% annually for the last half of the decade. The company achieved an average annual earnings per share of 19.18%. With a float of $61.36 million, this company’s outstanding shares have now reached $67.09 million.
Cardiff Oncology Inc (CRDF) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Cardiff Oncology Inc is 8.91%, while institutional ownership is 31.18%. The most recent insider transaction that took place on Jul 30 ’25, was worth 673,750. In this transaction Director of this company bought 275,000 shares at a rate of $2.45, taking the stock ownership to the 1,330,676 shares. Before that another transaction happened on Jul 30 ’25, when Company’s Director bought 15,000 for $2.45, making the entire transaction worth $36,750. This insider now owns 1,345,676 shares in total.
Cardiff Oncology Inc (CRDF) Latest Financial update
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.21 earnings per share (EPS) for the period topping the consensus outlook (set at -0.25) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 19.18% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 1.14% during the next five years compared to 19.36% growth over the previous five years of trading.
Cardiff Oncology Inc (NASDAQ: CRDF) Trading Performance Indicators
Cardiff Oncology Inc (CRDF) is currently performing well based on its current performance indicators. A quick ratio of 4.20 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 386.65.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.79, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.77 in one year’s time.
